Analysts have been eager to weigh in on the Healthcare sector with new ratings on Karyopharm Therapeutics (KPTI) and Momenta Pharma (MNTA).
Karyopharm Therapeutics (KPTI)
In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Karyopharm Therapeutics, with a price target of $30. The company’s shares opened today at $11.31.
White commented:
“We base our $30 price target on probability-adjusted revenue forecasts for selinexor. We use a net present value of our revenue forecast through 2026, apply a 50% probability of success (POS) for selinexor in penta- refractory multiple myeloma, a 35% POS for selinexor in combination treatment for multiple myeloma, and a 25% POS for selinexor in DLBCL. We use a 4x P/S multiple and estimated YE18 fully diluted net cash of $2.09/ share. Our P/S multiple of 4x is in-line with Karyopharm’s peers that range between 2-5x.”
According to TipRanks.com, White is a 5-star analyst with an average return of 14.0% and a 44.6% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Synthetic Biologics Inc.
Karyopharm Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $27.50.
See today’s analyst top recommended stocks >>
Momenta Pharma (MNTA)
In a report released today, Brandon Folkes from Cantor Fitzgerald reiterated a Hold rating on Momenta Pharma, with a price target of $16. The company’s shares opened today at $13.80, close to its 52-week low of $11.72.
Folkes said:
“. Post 3Q18, we reiterate our Neutral rating and are lowering our 12-month price target to $16 from $24. We view the company’s novel pipeline as potentially blockbuster, and Momenta, along with its partners, has proven the company’s expertise and ability to successfully develop complex products. However, given the early-stage nature of the company’s pipeline, and uncertainty around M281 safety profile, we remain on the sidelines at this valuation. We could be more constructive on MNTA stock if the company is able to advance its early-stage, novel drugs and show positive efficacy and safety data.”
According to TipRanks.com, Folkes is a 3-star analyst with an average return of 3.0% and a 51.9% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Opiant Pharmaceuticals Inc, and Eagle Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Momenta Pharma with a $33 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
